ST Premium

For just $1, you can unlock ST Grading’s top-rated stocks that consistently beat the market.Our AI-powered Smart Screener finds winning trades in seconds, helping you uncover hidden opportunities before others do.

Ready to Win Big?

Try Now for Just $1!

RXRX Company Profile and Key Details

NASDAQ : RXRX

Recursion Pharmaceuticals, Inc.

$5.76

1.25+27.72%

Open: 4:00 PM

73.23

BESG ScoreESG Rating

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

RXRX Stock Price Chart

Stock Price Today

Recursion Pharmaceuticals, Inc. (RXRX) stock surged +27.72%, trading at $5.76 on NASDAQ, up from the previous close of $4.51. The stock opened at $5.01, fluctuating between $4.86 and $6.00 in the recent session.

Stock Snapshot

4.51

Prev. Close

5.01

Open

2.28B

Market Cap

395.07M

Number of Shares

4.86

Day Low

Day High

-3.41

P/E Ratio

77.42%

Free Float in %

-1.69

EPS (TTM)

1.99

Book Value

-1.29

Cash Flow per Share

83M

Volume

Relevant Articles

Stock Price History Chart

Date	Open	High	Low	Close	Volume
Apr 11, 2025	5.00	6.00	4.86	5.76	82.93M
Apr 10, 2025	4.60	4.64	4.07	4.51	23.82M
Apr 09, 2025	3.89	4.97	3.79	4.65	35.25M
Apr 08, 2025	4.49	4.49	3.87	3.97	24.59M
Apr 07, 2025	3.96	4.60	3.80	4.20	24.95M
Apr 04, 2025	4.59	4.74	4.06	4.24	27.96M
Apr 03, 2025	4.91	5.03	4.78	4.81	18.11M
Apr 02, 2025	4.99	5.37	4.95	5.29	16.58M
Apr 01, 2025	5.32	5.34	5.00	5.10	16.83M
Mar 31, 2025	5.50	5.51	5.19	5.29	17.84M
Mar 28, 2025	5.95	6.01	5.77	5.81	15.01M
Mar 27, 2025	6.04	6.30	5.95	5.97	14.74M
Mar 26, 2025	6.52	6.54	6.08	6.17	15.11M
Mar 25, 2025	6.74	6.76	6.47	6.53	12M
Mar 24, 2025	6.83	6.94	6.66	6.79	16.03M
Mar 21, 2025	6.31	6.74	6.27	6.68	18.07M
Mar 20, 2025	6.50	6.76	6.40	6.48	14.32M
Mar 19, 2025	6.40	6.75	6.36	6.58	13.83M
Mar 18, 2025	6.58	6.61	6.22	6.39	17.73M
Mar 17, 2025	6.39	6.89	6.30	6.84	16.91M

Contact Details

Salt Lake City, UT 84101

United States

Website: https://www.recursion.comContact: 385 269 0203

About Company

Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase IIa clinical trial to treat cerebral cavernous malformation; REC-2282 for the treatment of neurofibromatosis type 2; REC-4881 to treat familial adenomatous polyposis; and REC-3599, which is in Phase I clinical trial to treat GM2 gangliosidosis. Its preclinical stage product includes REC-3964 to treat Clostridium difficile colitis; REC-64917 for the treat of neural or systemic inflammation; REC-65029 to treat HRD-negative ovarian cancer; REC-648918 to enhance anti-tumor immune; REC-2029 for the treatment of wnt-mutant hepatocellular carcinoma; REC-14221 to treat solid and hematological malignancies; and REC-64151 for the treatment of immune checkpoint resistance in KRAS/STK11 mutant non-small cell lung cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Chromaderm, Inc.; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.

Frequently Asked Questions

What is the current Recursion Pharmaceuticals, Inc. (RXRX) stock price?

Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) stock price is $5.76 in the last trading session. During the trading session, RXRX stock reached the peak price of $6.00 while $4.86 was the lowest point it dropped to. The percentage change in RXRX stock occurred in the recent session was 27.72% while the dollar amount for the price change in RXRX stock was $1.25.

RXRX's industry and sector of operation?

The NASDAQ listed RXRX is part of Biotechnology industry that operates in the broader Healthcare sector. Recursion Pharmaceuticals, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of RXRX?

Mr. Ryan Kelly
Managing Director
Dr. Michael Secora Ph.D.
Chief Financial Officer
Ms. Tina Marriott Larson
Chief Operating Officer & Pres
Ms. Louisa Daniels J.D., M.B.A.
Chief Legal Officer & Gen. Counsel
Kevin Leggat
Vice President of Fin. & Accounting
Dr. Blake C. Borgeson Ph.D.
Co-Founder & Director
Dr. Christopher C. Gibson Ph.D.
Co-Founder, Chief Executive Officer & Director
Mr. Benjamin Mabey M.S.
Chief Technology Officer
Dr. Shafique Virani M.D.
Chief Corporation Devel. Officer
Mr. Jared Allenbach
Senior Director of Investor Relations
Ms. Heather Kirkby M.B.A.
Chief People Officer

How RXRX did perform over past 52-week?

RXRX's closing price is 51.98% higher than its 52-week low of $3.79 where as its distance from 52-week high of $12.36 is -53.4%.

How many employees does RXRX have?

Number of RXRX employees currently stands at 800.

Link for RXRX official website?

Official Website of RXRX is: https://www.recursion.com

How do I contact RXRX?

RXRX could be contacted at phone 385 269 0203 and can also be accessed through its website. RXRX operates from 41 South Rio Grande Street, Salt Lake City, UT 84101, United States.

How many shares of RXRX are traded daily?

RXRX stock volume for the day was 83M shares. The average number of RXRX shares traded daily for last 3 months was 25.02M.

What is the market cap of RXRX currently?

The market value of RXRX currently stands at $2.28B with its latest stock price at $5.76 and 395.07M of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

About

Home About Meet The Team Contact Us Privacy Policy Newsletter

Employees	800
Beta	0.99
Sales or Revenue	$44.58M
5Y Sales Change%	19.78%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Biotechnology